Effectiveness of chemotherapy using bortezomib combined with homoharringtonine and cytarabine in refractory or relapsed acute myeloid leukemia: a phase II, multicenter, prospective clinical trial

BackgroundRefractory/relapsed acute myeloid leukemia (R/R AML) has unsatisfactory outcomes even after allogeneic hematopoietic stem cell transplantation. Long-term survival is mainly influenced by complete remission (CR) rates after induction therapies.ObjectivesTo investigate CR/CR with incomplete...

Full description

Bibliographic Details

Main Authors:	Chengtao Zhang, Da Gao, Xiaohong Wang, Xiuli Sun, Yan Yan, Yan Yang, Jingjing Zhang, Jinsong Yan
Format:	Artigo
Language:	Inglês
Published:	Frontiers Media S.A. 2023-08-01
Series:	Frontiers in Oncology
Subjects:	acute myeloid leukemia refractory and relapsed bortezomib homoharringtonine FLT3 mutation induction
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1142449/full
Tags:	Add Tag No Tags, Be the first to tag this record!